Prevention of tuberculosis in Bacille Calmette-Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine.
about
Tuberculosis vaccines: beyond bacille Calmette-GuerinTB vaccine development and the End TB Strategy: importance and current status.Tuberculosis vaccines and prevention of infectionApplication of radiation technology in vaccines developmentVaccine development for tuberculosis: current progressRecent advances towards tuberculosis control: vaccines and biomarkersEvaluation of tuberculosis diagnostics in children: 1. Proposed clinical case definitions for classification of intrathoracic tuberculosis disease. Consensus from an expert panel.The Progress of Therapeutic Vaccination with Regard to TuberculosisAdjunct Strategies for Tuberculosis Vaccines: Modulating Key Immune Cell Regulatory Mechanisms to Potentiate VaccinationRandomized, placebo-controlled phase II trial of heat-killed Mycobacterium vaccae (Longcom batch) formulated as an oral pill (V7)Mycobacterium vaccae induces a strong Th1 response that subsequently declines in C57BL/6 miceTuberculosis vaccines: barriers and prospects on the quest for a transformative toolDC priming by M. vaccae inhibits Th2 responses in contrast to specific TLR2 priming and is associated with selective activation of the CREB pathwayNovel vaccination strategies against tuberculosis.Toward novel vaccines against tuberculosis: current hopes and obstacles.Polyantigenic interferon-γ responses are associated with protection from TB among HIV-infected adults with childhood BCG immunization.Oral Administration of Heat-Killed Mycobacterium manresensis Delays Progression toward Active Tuberculosis in C3HeB/FeJ Mice.Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: A randomized, controlled trial of DAR-901.A chromosome 5q31.1 locus associates with tuberculin skin test reactivity in HIV-positive individuals from tuberculosis hyper-endemic regions in east Africa.Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.Immunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: a phase III study in TanzaniaDiagnosis and treatment of tuberculosis among children at an HIV care program in Dar es Salaam, TanzaniaSafety and immunogenicity of H1/IC31®, an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trial.Low BMI and falling BMI predict HIV-associated tuberculosis: a prospective study in TanzaniaSubunit vaccine consisting of multi-stage antigens has high protective efficacy against Mycobacterium tuberculosis infection in mice.Vaccine against tuberculosis: what's new?Diagnosing latent tuberculosis in high-risk individuals: rising to the challenge in high-burden areas.Intracellular Cytokine Staining and Flow Cytometry: Considerations for Application in Clinical Trials of Novel Tuberculosis VaccinesA phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adultsOpportunities and challenges for cost-efficient implementation of new point-of-care diagnostics for HIV and tuberculosis.A Locus at 5q33.3 Confers Resistance to Tuberculosis in Highly Susceptible Individuals.Molecular epidemiology of HIV-associated tuberculosis in Dar es Salaam, Tanzania: strain predominance, clustering, and polyclonal diseaseImmunogenicity and Protective Efficacy of the DAR-901 Booster Vaccine in a Murine Model of Tuberculosis.T Cell Responses against Mycobacterial Lipids and Proteins Are Poorly Correlated in South African Adolescents.Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial.Current and novel approaches to vaccine development against tuberculosis.Recurrent tuberculosis risk among HIV-infected adults in Tanzania with prior active tuberculosisAdvances in the Diagnosis, Treatment and Control of HIV Associated TuberculosisIncreased mortality associated with treated active tuberculosis in HIV-infected adults in Tanzania.HIV and co-infections.
P2860
Q22242669-9678FC6C-942B-4629-8934-521F1C1DCAD7Q26748621-817E7F00-FB10-4949-9B75-373CBDABDC20Q26782022-EC68CFEB-F18F-46E0-8737-A17F164A8D5BQ26798165-58E56B8B-E425-479D-9ECF-0CE22E5975CFQ26827737-07EE6DD0-A5EB-4676-8B89-EF291345E14AQ26859739-52A17CF0-9116-4615-93E2-C933F3073A86Q27690864-7CEF29F4-A717-4927-BB3F-B99554252990Q28072271-855B71F2-A675-4C12-92CB-70704F4AC281Q28074536-0EB66B04-1C85-43E0-AFB6-07251303FFD2Q28293125-3F492951-E3FA-47B8-84CF-AEF068D5B2CBQ28356383-9C0AAFF0-4171-4A07-85EC-62CE28728D4EQ28390218-5CE12B8D-4CC5-4DEB-8218-01096A4BACC2Q28741435-93EF8F28-9C4C-4F1C-BD76-153BE713E9F0Q30363188-66EFBEB9-8C0E-4B18-A0B6-10F4BDBEEF5EQ30484783-60D0FD5F-C27D-4A7C-91BC-DC30E1BFB6DCQ31026796-5AC69244-110F-42BA-B04D-BAD77C034D22Q31037455-8B3E3C9E-1CCA-4115-A94D-1E59EC3DD10BQ33675370-BA92BC8D-6F33-4429-A812-2140E65EE70CQ33866343-22900DE1-79D9-4A4F-B905-96AE6F9F029DQ34055234-62613FD0-6BED-43BA-AE39-C6A85C6EFFFCQ34312118-C2EFFD46-5C8E-4D38-BB4E-4989341568DAQ34498598-EEA0712D-E188-435D-8A91-0ABD3AFC2C29Q34663035-20D008C7-5CC6-4324-B74E-49328ECD4773Q34745112-0AE947CB-476D-40CB-B9A1-947C55B43BE2Q34965575-C00972D9-D93C-4580-B298-8F605ADFAC95Q35101472-3A059C8A-A59E-4C4B-8945-A0C947E4382AQ35336540-391DB377-4D19-4F73-AD12-2669A4DCE8DEQ35772893-922B636D-19AC-4097-8FD9-121F5CBCC501Q35889153-C72C6041-9811-4744-9288-B55250300122Q35907384-E0A8FED1-A743-4912-8D52-99A61E2F7D40Q35945786-49179A8A-4AB2-4935-9C8E-B8D06EF69C37Q36171368-4F55A561-F8F5-40BA-A8BF-C37D8A681C0AQ36229621-8387E97B-E6A6-4893-9176-2A463D1093C1Q36260275-6EE06641-2303-4D29-95C4-A1435B4AF308Q36287555-003D5617-DE14-4C18-8F67-019A70666A00Q36449189-48F384DB-55CD-4004-B203-B844AF804CB4Q36457649-9C19DACF-FE39-4827-9D44-85F04A035ADAQ36627619-A234BB43-C6E2-4EA8-91B7-677BA99FE310Q36927041-2A459A27-EA06-47D4-A833-7AC7CDF9982CQ36970184-F945E4A6-AE6A-4FF8-B451-8E928B36E903
P2860
Prevention of tuberculosis in Bacille Calmette-Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Prevention of tuberculosis in ...... le-cell mycobacterial vaccine.
@en
Prevention of tuberculosis in ...... le-cell mycobacterial vaccine.
@nl
type
label
Prevention of tuberculosis in ...... le-cell mycobacterial vaccine.
@en
Prevention of tuberculosis in ...... le-cell mycobacterial vaccine.
@nl
prefLabel
Prevention of tuberculosis in ...... le-cell mycobacterial vaccine.
@en
Prevention of tuberculosis in ...... le-cell mycobacterial vaccine.
@nl
P2093
P1433
P1476
Prevention of tuberculosis in ...... le-cell mycobacterial vaccine.
@en
P2093
Bernard Cole
Charles F von Reyn
DarDar Study Group
Kisali Pallangyo
Lillian Mtei
Lisa V Adams
Mecky Matee
Muhammad Bakari
Richard Waddell
Robert D Arbeit
P304
P356
10.1097/QAD.0B013E3283350F1B
P407
P50
P577
2010-03-01T00:00:00Z